Prime Medicine, Inc. announced the pricing of an underwritten public offering of 38,000,000 shares of its common stock at $3.30 per share, aiming to raise approximately $125.4 million. The offering is expected to close around August 1, 2025. The company granted underwriters a 30-day option to acquire up to an additional 5,700,000 shares. The shares are being sold by Prime Medicine, and TD Cowen and BMO Capital Markets are acting as joint book-running managers. The offering is made via an effective shelf registration statement with the SEC, and a prospectus supplement is available on the SEC’s website.

Prime Medicine is a biotechnology company focused on gene editing therapies, using its proprietary Prime Editing platform to develop one-time curative genetic therapies. The company is working on therapeutic programs in liver, lung, immunology, and oncology. Forward-looking statements in the press release caution about risks and uncertainties related to the public offering and market conditions. Investors and media can contact Gregory Dearborn at Prime Medicine or Hannah Deresiewicz at Precision AQ for more information.

Read more at GlobeNewswire: Prime Medicine Announces Pricing of Public Offering